Product nameAnti-PPAR gamma antibody
See all PPAR gamma primary antibodies
DescriptionRabbit polyclonal to PPAR gamma
Tested applicationsSuitable for: IPmore details
Unsuitable for: WB
Species reactivityReacts with: Mouse
Predicted to work with: Dog, Human, Pig, Chimpanzee, Cynomolgus monkey, Rhesus monkey, Gorilla, Orangutan
Synthetic peptide within Human PPAR gamma aa 100-150. The exact sequence is proprietary. (NP_056953.2).
Database link: P37231
- IP: NIH/3T3-L1 whole cell lysate.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituent: Tris citrate/phosphate
pH 7 to 8
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab226183 was affinity purified using an epitope specific to PPAR gamma immobilized on solid support.
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
Our Abpromise guarantee covers the use of ab226183 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IP||Use at 2-10 µg/mg of lysate.|
FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Information by UniProt
- CIMT1 antibody
- GLM1 antibody
- NR1C3 antibody
PPAR gamma was immunoprecipitated from NIH/3T3-L1 whole cell lysate (prepared using NETN lysis buffer; 1 mg for IP, 20% of IP loaded) with ab226183 at 6 µg/mg lysate. Western blot was performed from the immunoprecipitate using ab226183 at 0.1 µg/ml.
Lane 1: ab226183 IP in NIH/3T3-L1 whole cell lysate.
Lane 2: Control IgG IP in NIH/3T3-L1 whole cell lysate.
Detection: Chemiluminescence with exposure time of 3 minutes.
ab226183 has not yet been referenced specifically in any publications.